Investment Analysts’ Recent Ratings Updates for Exelixis (EXEL)

Exelixis (NASDAQ: EXEL) has recently received a number of price target changes and ratings updates:

• 11/2/2026 – Exelixis had its price target raised by HC Wainwright from $56.00 to $78.00. They now have a “buy” rating on the stock.
• 11/1/2026 – Exelixis was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/30/2026 – Exelixis had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $60.00 price target on the stock.
• 10/30/2026 – Exelixis had its price target raised by TD Cowen from $55.00 to $76.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Exelixis had its price target raised by Morgan Stanley from $53.00 to $60.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Exelixis had its price target raised by Truist Financial from $54.00 to $60.00. They now have a “hold” rating on the stock.
• 10/30/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $51.00 to $58.00. They now have a “sector perform” rating on the stock.
• 10/30/2026 – Exelixis had its price target raised by Barclays from $49.00 to $54.00. They now have an “equal weight” rating on the stock.
• 10/24/2026 – Exelixis was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 10/19/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup.
• 10/19/2026 – Exelixis had its price target raised by Citizens Jmp from $55.00 to $65.00. They now have a “market outperform” rating on the stock.
• 10/9/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $45.00 to $51.00. They now have a “sector perform” rating on the stock.
• 10/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (a-)” to “buy (a)”.
• 10/8/2026 – Exelixis had its price target lowered by Royal Bank Of Canada from $46.00 to $45.00. They now have a “sector perform” rating on the stock.
• 10/7/2026 – Exelixis had its price target raised by Truist Financial from $52.00 to $54.00. They now have a “hold” rating on the stock.
• 9/14/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup.
• 9/11/2026 – Exelixis had its “outperform” rating reaffirmed by William Blair.

Exelixis Price Performance

Shares of EXEL stock traded up $2.13 on Tuesday, hitting $72.26. 2,488,488 shares of the company’s stock were exchanged, compared to its average volume of 2,601,847. The company has a 50 day moving average of $59.71 and a 200 day moving average of $51.05. The stock has a market cap of $17.90 billion, a P/E ratio of 21.63, a price-to-earnings-growth ratio of 1.86 and a beta of 0.47. Exelixis, Inc. has a 12 month low of $37.58 and a 12 month high of $73.44.

Exelixis (NASDAQ:EXEL) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.05. The firm had revenue of $658.70 million for the quarter, compared to analysts’ expectations of $646.51 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.78 earnings per share. Sell-side analysts predict that Exelixis, Inc. will post 3.19 EPS for the current fiscal year.

Insider Transactions at Exelixis

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares of the company’s stock, valued at $862,799.14. This represents a 37.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by corporate insiders.

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.